Chengda Biology (688739.SH): Influenza virus lysis vaccine (high dose) enters phase I clinical trial

Zhitongcaijing · 1d ago

Zhitong Finance App News, Chengda Biotech (688739.SH) issued an announcement. Recently, the influenza virus lytic vaccine (high dose) developed by Chengda Biology (Benxi) Co., Ltd. (“Benxi subsidiary”), a wholly-owned subsidiary of the company, has obtained clinical trial approval from the State Drug Administration and completed all preparations for the phase I clinical trial, and officially entered the phase I clinical trial stage.

Phase I clinical trials of the influenza virus lysis vaccine (high dose) have started, indicating phased progress in the development of this product. The Benxi subsidiary will strictly comply with the relevant clinical trial regulations and test plan requirements, and steadily advance follow-up clinical research on this product. This product differentiates and complements the influenza virus lysis vaccine and quadrivalent influenza virus lytic vaccine that the company has approved for marketing, in terms of product positioning and application groups, and can further improve the company's product lineup in the field of influenza vaccines. If this product is successfully developed and launched in the future, it will effectively expand the company's vaccine product pipeline, enrich the product structure, and lay a solid foundation for the company's continuous and steady development.